Snapshot
- Ticker: AMBQ (NYSE); IPO July 30, 2025 at $24/share
- Bucket: Compute & AI Megacaps
- Q1 2026 position: 862,175 shares, $21.9M, 0.44% of 13F
- HQ: Austin, Texas
- What it does: Fabless designer of ultra-low-power microcontrollers and SoCs (Apollo family) built on subthreshold/near-threshold transistor operation, targeting always-on edge-AI in wearables, medical, and industrial devices.
Business Overview
Ambiq’s SPOT (Subthreshold Power Optimized Technology) platform runs logic at voltages far below conventional designs, delivering multi-fold power savings — the enabling trick for battery-constrained devices that need to run AI inference continuously. Its Apollo SoCs dominate power-sensitive wearables and are pushing into medical, industrial, and smart-building markets.
The company IPO’d in July 2025, raising 25.1M, up 59.3% year over year, with gross margin of 43.5%. It is still pre-profit: management says ~204.5M of cash (boosted by a $75.3M January 2026 follow-on). Customer concentration is falling, and management expects medical, industrial, and smart-home segments to each grow >100% in 2026. The next-gen Apollo 340 samples in H1 2027 with substantial revenue projected for 2028.
Why Atreides Owns It
Ambiq is the edge-AI corner of Baker’s compute thesis — the inverse of the datacenter watts problem. If power is the binding constraint of AI everywhere, the company whose entire moat is joules-per-inference is a pure expression of “watts” at milliwatt scale: inference migrating to devices that can’t carry a fan, let alone a grid connection. It is also a crossover IPO-cohort position: Atreides appeared on the register in Q3 2025, the IPO quarter, consistent with an allocation at or near the $24 offering — part of the same IPO flywheel as CoreWeave, Chime, and BitGo. Sizing (~0.4%) marks it as a venture-style public position: small, early, optionality-weighted, with the Q1 2026 add (+24% shares) suggesting the fund participated in or added around the January follow-on.
Position History
| Quarter | Type | Shares/Notional | Value | % of 13F |
|---|---|---|---|---|
| Q4 2024 | — | not held | — | — |
| Q1 2025 | — | not held | — | — |
| Q2 2025 | — | not held | — | — |
| Q3 2025 | Common | 684,307 | $20,474,465 | 0.40% |
| Q4 2025 | Common | 696,420 | $19,847,970 | 0.24% |
| Q1 2026 | Common | 862,175 | $21,907,867 | 0.44% |
Entered in Q3 2025 — the IPO quarter — and added steadily since, never trimmed: the quiet-accumulation pattern of the fund’s IPO-cohort names, in contrast to the violent CoreWeave round-trip.
Risks
- Pre-profit and small: ~$100M-revenue-scale company needing roughly double current quarterly revenue to break even; further dilution is plausible.
- Customer concentration: historically dependent on a few large wearables customers; diversification is in progress, not done.
- Competition: Nordic, Silicon Labs, Qualcomm, and Ampere-class MCU vendors are all converging on low-power edge AI; SPOT’s lead must be defended each node.
- Edge-AI timing risk: the thesis requires on-device inference to monetize on Ambiq’s timeline; the Apollo 340 payoff is a 2028 story.
- IPO-cohort overhang: lockup releases and concentrated early holders make the stock technically fragile.
Sources
- https://www.stocktitan.net/news/AMBQ/ambiq-reports-first-quarter-2026-financial-4empw70fert3.html
- https://www.aol.com/articles/ambiq-micro-ambq-q1-2026-165500000.html
- https://ir.ambiq.com/news/news-details/2025/Ambiq-Announces-Closing-of-its-Upsized-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares/default.aspx
- https://stockanalysis.com/stocks/ambq/